By vgreene, 10 July, 2019 HER2 status:1,2 to identify candidates for trastuzumab, pertuzumab, or lapatinib
By vgreene, 10 July, 2019 Microsatellite Instability (MSI)1,2 to identify CRC pts at high risk for Lynch syndrome and/or prognostic stratification;3 recommended in all pts w/ personal Hx of colon/rectal CA;1,2 MSI testing may be accomplished w/ a validated NGS panel (esp in pts w/
By vgreene, 10 July, 2019 DNA Mismatch Repair (MMR) genes (MLHI, MSH2, MSH6 or PMS2 mutations)1,2 leading to lack of protein expression; to identify CRC pts at high risk for Lynch syndrome and/or prognostic stratification;3 recommended in all pts w/ personal Hx of colon/rectal CA1
By vgreene, 10 July, 2019 If recurrent or Stage IV HER2(-) invasive breast CA AND candidate for chemo tx, consider:
By vgreene, 10 July, 2019 MammaPrint (70-gene assay): recommended in pts w/ 1-3 positive nodes who ALSO have high clinical risk as defined by MINDACT categorization to inform decisions on withholding adjuvant systemic chemotx2